ocr: Series Sarcoma Type Drug Patients CR + PR Endpoints or Comments Omura et al.925 All DOX 80 5+8 Median survival 7.7 months; response 25% for LMS vs. DOX + DTIC 66 7+9 Median survival 7.3 months; response 30% for LMS Muss et al.256 All DOX 26 5 Median survival 11.6 months vs. DOX + CTX 26 5 Median survival 10.5 months Sutton ct al. 228 LMS DOX + IFX 27 1+9 Thigpen et al.287 LMS CDDP 10 0+1 Prior treatment; less responsive than MMT Sutton et al.297 LMS IFX 35 0+6 No prior treatment; less responsive than MMT Thigpen et al.251 LMS CDDP 33 0+7 No prior treatment; less responsive than MMI Slayton et ...
